NEW IMMUNOTHERAPY STRATEGIES FOR MELANOMA: CHECKPOINT INHIBITORS, COMBINATION THERAPIES AND mRNA VACCINES
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6418Keywords:
Melanoma, Immunotherapy, Immune Checkpoint Inhibitors, Targeted Therapy, BRAF Inhibitors, mRNA Vaccines, Combination Therapy, Precision OncologyAbstract
Melanoma remains one of the most aggressive forms of skin cancer; however, the development of modern immunotherapeutic strategies has significantly improved the prognosis for a subset of patients. This review aims to discuss current and emerging treatment approaches based on modulation of the immune response, with particular emphasis on immune checkpoint inhibitors, targeted therapies, and mRNA vaccines. The mechanisms of action of antibodies targeting CTLA-4 and PD-1/PD-L1, their clinical efficacy, and the characteristic immune-related adverse events are presented. The review also discusses targeted therapies directed against BRAF and MEK mutations, as well as the rationale for combining these agents with immunotherapy to overcome treatment resistance. Furthermore, the emerging role of personalized mRNA vaccines designed according to the tumor neoantigen profile and the preliminary results of clinical trials are summarized. The importance of predictive biomarkers for patient selection and future directions in combination therapies are also highlighted. Overall, this review synthesizes the current state of knowledge and outlines promising opportunities for further improving treatment outcomes in patients with melanoma.
References
Arnold, M., Singh, D., Laversanne, M., Vignat, J., Vaccarella, S., Meheus, F., Cust, A., De Vries, E., Whiteman, D., & Bray, F. (2022). Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2022.0160
Arozarena, I., & Wellbrock, C. (2017). Overcoming resistance to BRAF inhibitors. Annals of Translational Medicine, 5(19), 387. https://doi.org/10.21037/atm.2017.06.09
Bafaloukos, D., Gazouli, I., Koutserimpas, C., & Samonis, G. (2023). Evolution and progress of mRNA vaccines in the treatment of melanoma: Future prospects. Vaccines, 11. https://doi.org/10.3390/vaccines11030636
Batista-Duharte, A., Hassouneh, F., Álvarez-Heredia, P., Pera, A., & Solana, R. (2022). Immune checkpoint inhibitors for vaccine improvements: Current status and new approaches. Pharmaceutics, 14. https://doi.org/10.3390/pharmaceutics14081721
Blass, E., & Ott, P. (2021). Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nature Reviews. Clinical Oncology, 18, 215–229. https://doi.org/10.1038/s41571-020-00460-2
Broderick, J., Adams, A., Barbera, E., Van Decar, S., Clifton, G., & Peoples, G. (2025). Melanoma vaccines: Comparing novel adjuvant treatments in high-risk patients. Vaccines, 13. https://doi.org/10.3390/vaccines13060656
Carlino, M., Larkin, J., & Long, G. (2021). Immune checkpoint inhibitors in melanoma. Lancet, 398(10304), 1002–1014. https://doi.org/10.1016/s0140-6736(21)01206-x
Chang, C., Park, H., Malone, D., Wang, C., Wilson, D., Yeh, Y., Van Boemmel-Wegmann, S., & Lo‐Ciganic, W. (2020). Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma. JAMA Network Open, 3. https://doi.org/10.1001/jamanetworkopen.2020.1611
Choi, Y., Seok, S., Yoon, H., Ryu, J., & Kwon, I. (2024). Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade. Advanced Drug Delivery Reviews, 115306. https://doi.org/10.1016/j.addr.2024.115306
De Pinto, G., Mignozzi, S., La Vecchia, C., Levi, F., Negri, E., & Santucci, C. (2024). Global trends in cutaneous malignant melanoma incidence and mortality. Melanoma Research, 34, 265–275. https://doi.org/10.1097/cmr.0000000000000959
Dummer, R., Ascierto, P., Nathan, P., Robert, C., & Schadendorf, D. (2020). Rationale for immune checkpoint inhibitors plus targeted therapy in metastatic melanoma: A review. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2020.4401
Dutta, S., Ganguly, A., Chatterjee, K., Spada, S., & Mukherjee, S. (2023). Targets of immune escape mechanisms in cancer: Basis for development and evolution of cancer immune checkpoint inhibitors. Biology, 12. https://doi.org/10.3390/biology12020218
Floudas, C., Sarkizova, S., Ceccarelli, M., & Zheng, W. (2025). Leveraging mRNA technology for antigen based immuno-oncology therapies. Journal for Immunotherapy of Cancer, 13. https://doi.org/10.1136/jitc-2024-010569
Fu, Q., Zhao, X., Hu, J., Jiao, Y., Yan, Y., Pan, X., Wang, X., & Jiao, F. (2025). mRNA vaccines in the context of cancer treatment: From concept to application. Journal of Translational Medicine, 23. https://doi.org/10.1186/s12967-024-06033-6
Furue, M., Ito, T., Wada, N., Wada, M., Kadono, T., & Uchi, H. (2018). Melanoma and immune checkpoint inhibitors. Current Oncology Reports, 20, 1–8. https://doi.org/10.1007/s11912-018-0676-z
Gao, C., Duan, X., Peng, L., Zhao, Y., Li, P., & Mou, K. (2026). Melanoma vaccines: Current R&D landscape, translational hurdles, and future outlook—a perspective drawn from 442 clinical trials. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1698503
Gide, T., Wilmott, J., Scolyer, R., & Long, G. (2017). Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clinical Cancer Research, 24, 1260–1270. https://doi.org/10.1158/1078-0432.ccr-17-2267
Han, R., Rao, X., Zhou, H., & Lu, L. (2024). Synergistic immunoregulation: Harnessing CircRNAs and PiRNAs to amplify PD-1/PD-L1 inhibition therapy. International Journal of Nanomedicine, 19, 4803–4834. https://doi.org/10.2147/ijn.s461289
Han, R., Wang, Y., & Lu, L. (2023). Sensitizing the efficiency of ICIs by neoantigen mRNA vaccines for HCC treatment. Pharmaceutics, 16. https://doi.org/10.3390/pharmaceutics16010059
Imani, S., Roozitalab, G., Emadi, M., Moradi, A., Behzadi, P., & Kaboli, P. (2024). The evolution of BRAF-targeted therapies in melanoma: Overcoming hurdles and unleashing novel strategies. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1504142
Karlsson, A., & Saleh, S. (2017). Checkpoint inhibitors for malignant melanoma: A systematic review and meta-analysis. Clinical, Cosmetic and Investigational Dermatology, 10, 325–339. https://doi.org/10.2147/ccid.s120877
Khaddour, K., & Buchbinder, E. (2025). Individualized neoantigen-directed melanoma therapy. American Journal of Clinical Dermatology, 26, 225–235. https://doi.org/10.1007/s40257-025-00920-4
Khan, A., Aziz, N., Akram, U., Amin, M., Begiashvili, V., Warraich, S., Anwar, I., Mushtaq, M., Park, R., Jaglal, M., & Shahzad, M. (2025). Outcomes with targeted therapy for NRAS-mutated melanoma: A systematic review and meta-analysis. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.e21506
Khattak, A., Weber, J., Meniawy, T., Taylor, M., Ansstas, G., Kim, K., McKean, M., Long, G., Sullivan, R., Faries, M., Tran, T., Cowey, C., Medina, T., Segar, J., Atkinson, V., Gibney, G., Luke, J., Buchbinder, E., Meehan, R., & Carlino, M. (2023). Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2023.41.17_suppl.lba9503
Kim, C., Lee, J., Shin, S., Ahn, J., Lee, M., & Kim, H. (2022). The efficacy of immune checkpoint inhibitors in elderly patients: A meta-analysis and meta-regression. ESMO Open, 7. https://doi.org/10.1016/j.esmoop.2022.100577
Klemen, N., Wang, M., Rubinstein, J., Olino, K., Clune, J., Ariyan, S., Cha, C., Weiss, S., Kluger, H., & Sznol, M. (2020). Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma. Journal for Immunotherapy of Cancer, 8. https://doi.org/10.1136/jitc-2019-000341
Knight, A., Karapetyan, L., & Kirkwood, J. (2023). Immunotherapy in melanoma: Recent advances and future directions. Cancers, 15. https://doi.org/10.3390/cancers15041106
Kyte, J., Aamdal, S., Dueland, S., Sæbøe-Larsen, S., Inderberg, E., Madsbu, U., Skovlund, E., Gaudernack, G., & Kvalheim, G. (2016). Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells. OncoImmunology, 5. https://doi.org/10.1080/2162402x.2016.1232237
Latifyan, S., & Haanen, J. (2024). Melanoma neoantigen vaccines: Are we getting more personal now? Med, 5(4), 288–290. https://doi.org/10.1016/j.medj.2024.03.004
Lelliott, E., McArthur, G., Oliaro, J., & Sheppard, K. (2021). Immunomodulatory effects of BRAF, MEK, and CDK4/6 inhibitors: Implications for combining targeted therapy and immune checkpoint blockade for the treatment of melanoma. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.661737
Lengyel, A., Meznerics, F., Galajda, N., Gede, N., Kói, T., Mohammed, A., Péter, P., Lakatos, A., Krebs, M., Csupor, D., Bánvölgyi, A., Hegyi, P., Holló, P., & Kemény, L. (2024). Safety and efficacy analysis of targeted and immune combination therapy in advanced melanoma—a systematic review and network meta-analysis. International Journal of Molecular Sciences, 25. https://doi.org/10.3390/ijms252312821
Lens, M., & Schachter, J. (2025). Immune checkpoint inhibitors in the treatment of advanced melanoma in older patients: An overview of published data. Cancers, 17. https://doi.org/10.3390/cancers17111835
Li, J., Kan, H., Zhao, L., Sun, Z., & Bai, C. (2020). Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: A systematic review. Therapeutic Advances in Medical Oncology, 12. https://doi.org/10.1177/1758835920922028
Li, Y., Liang, X., Li, H., & Chen, X. (2023). Comparative efficacy and safety of immune checkpoint inhibitors for unresectable advanced melanoma: A systematic review and network meta-analysis. International Immunopharmacology, 115, 109657. https://doi.org/10.1016/j.intimp.2022.109657
Lim, S., Menzies, A., & Rizos, H. (2017). Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Cancer, 123. https://doi.org/10.1002/cncr.30435
Liu, C., Liu, X., Hu, L., Li, X., Xin, H., & Zhu, S. (2024). Global, regional, and national burden of cutaneous malignant melanoma from 1990 to 2021 and prediction to 2045. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1512942
Long, G., Carlino, M., Au-Yeung, G., Spillane, A., Shannon, K., Gyorki, D., Hsiao, E., Kapoor, R., Thompson, J., Batula, I., Howle, J., Ch’ng, S., Gonzalez, M., Saw, R., Pennington, T., Lo, S., Scolyer, R., & Menzies, A. (2024). Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: The randomized phase 2 neotrio trial. Nature Medicine, 30, 2540–2548. https://doi.org/10.1038/s41591-024-03077-5
Lu, C., & Tan, Y. (2024). Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party. Molecular Therapy Oncology, 32. https://doi.org/10.1016/j.omton.2024.200773
Luke, J., Flaherty, K., Ribas, A., & Long, G. (2017). Targeted agents and immunotherapies: Optimizing outcomes in melanoma. Nature Reviews Clinical Oncology, 14, 463–482. https://doi.org/10.1038/nrclinonc.2017.43
Mauricio, D., Zeybek, B., Tymon-Rosario, J., Harold, J., & Santin, A. (2021). Immunotherapy in cervical cancer. Current Oncology Reports, 23. https://doi.org/10.1007/s11912-021-01052-8
Mehta, A., Motavaf, M., Nebo, I., Luyten, S., Osei-Opare, K., & Gru, A. (2025). Advancements in melanoma treatment: A review of PD-1 inhibitors, T-VEC, mRNA vaccines, and tumor-infiltrating lymphocyte therapy in an evolving landscape of immunotherapy. Journal of Clinical Medicine, 14. https://doi.org/10.3390/jcm14041200
Menzer, C., Dugas-Breit, S., Dugas, M., Blank, C., Groen, E., Reijers, I., Schlaak, M., Eckardt, J., Suijkerbuijk, K., Zimmer, L., Johnson, D., Franklin, C., Meiss, F., Schilling, B., Meier, F., Gutzmer, R., Thoms, K., Haalck, T., Müller, M., …, Hassel, J. (2025). Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome database. European Journal of Cancer, 228, 115703. https://doi.org/10.1016/j.ejca.2025.115703
Minnaert, A., Vanluchene, H., Verbeke, R., Lentacker, I., De Smedt, S., Raemdonck, K., Sanders, N., & Remaut, K. (2021). Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across. Advanced Drug Delivery Reviews, 176, 113900–113900. https://doi.org/10.1016/j.addr.2021.113900
Orlova, K., Ledin, E., Zhukova, N., Orlova, R., Karabina, E., Volkonskiy, M., Stroyakovskiy, D., Yurchenkov, A., Protsenko, S., Novik, A., Vorotilina, L., Moiseenko, F., Chang, V., Kazmin, A., Tkachenko, S., Gamaunov, S., Naskhletashvili, D., Samoylenko, I., Vikhrova, A., …, Demidov, L. (2021). Real-world experience with targeted therapy in BRAF mutant advanced melanoma patients: Results from a multicenter retrospective observational study advanced melanoma in Russia (experience) (ADMIRE). Cancers, 13. https://doi.org/10.3390/cancers13112529
Ott, P., Hu, Z., Keskin, D., Shukla, S., Sun, J., Bozym, D., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., Chen, C., Olive, O., Carter, T., Li, S., Lieb, D., Eisenhaure, T., Gjini, E., Stevens, J., Lane, W., …, Wu, C. (2017). An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 547, 217–221. https://doi.org/10.1038/nature22991
Pala, L., De Pas, T., Pagan, E., Minucci, S., Catania, C., Digiacomo, N., Cocorocchio, E., Laszlo, D., Muzio, A., Barigazzi, C., Stucchi, E., De Grandi, L., Stucchi, S., Viale, G., Gelber, R., Bagnardi, V., & Conforti, F. (2023). Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. a systematic review and meta-analysis. Seminars in Oncology. https://doi.org/10.1053/j.seminoncol.2023.03.003
Patel, M., Eckburg, A., Gantiwala, S., Hart, Z., Dein, J., Lam, K., & Puri, N. (2021). Resistance to molecularly targeted therapies in melanoma. Cancers, 13. https://doi.org/10.3390/cancers13051115
Pelster, M., & Amaria, R. (2019). Combined targeted therapy and immunotherapy in melanoma: A review of the impact on the tumor microenvironment and outcomes of early clinical trials. Therapeutic Advances in Medical Oncology, 11. https://doi.org/10.1177/1758835919830826
Pippa, C., Nicolas, M., Rossana, B., Massimo, G., Maximilian, S., Spyros, K., Bérengère, M., Jean-Baptiste, T., & Philippe, L. (2022). Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis. Cancer Treatment Reviews, 110, 102463. https://doi.org/10.1016/j.ctrv.2022.102463
Qu, T., Li, B., & Wang, Y. (2022). Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed. Biomarker Research, 10. https://doi.org/10.1186/s40364-022-00373-5
Queirolo, P., Boutros, A., Tanda, E., Spagnolo, F., & Quaglino, P. (2019). Immune-checkpoint inhibitors for the treatment of metastatic melanoma: A model of cancer immunotherapy. Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2019.08.001
Randic, T., Kozar, I., Margue, C., Utikal, J., & Kreis, S. (2021). NRAS mutant melanoma: Towards better therapies. Cancer Treatment Reviews, 99, 102238. https://doi.org/10.1016/j.ctrv.2021.102238
Sabbatino, F., Liguori, L., Pepe, S., & Ferrone, S. (2022). Immune checkpoint inhibitors for the treatment of melanoma. Expert Opinion on Biological Therapy, 22, 563–576. https://doi.org/10.1080/14712598.2022.2038132
Schadendorf, D., Van Akkooi, A., Berking, C., Griewank, K., Gutzmer, R., Hauschild, A., Stang, A., Roesch, A., & Ugurel, S. (2018). Melanoma. The Lancet, 392, 971–984. https://doi.org/10.1016/s0140-6736(18)31559-9
Shah, V., Panchal, V., Shah, A., Vyas, B., Agrawal, S., & Bharadwaj, S. (2024). Immune checkpoint inhibitors in metastatic melanoma therapy (review). Medicine International, 4. https://doi.org/10.3892/mi.2024.137
Sheng, F., Yan, Y., & Zeng, B. (2023). Efficacy and safety of immune checkpoint inhibitors and targeted therapies in resected melanoma: A systematic review and network meta-analysis. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1284240
Sisk, C., Turner, L., Meraj, S., & Yusuf, N. (2026). Advances in mRNA-Based melanoma vaccines: A narrative review of lipid nanoparticle and dendritic cell delivery platforms. Cells, 15. https://doi.org/10.3390/cells15020099
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & , D. (2023). Immune checkpoint therapy for solid tumours: Clinical dilemmas and future trends. Signal Transduction and Targeted Therapy, 8. https://doi.org/10.1038/s41392-023-01522-4
Sun, W., Hu, S., & Wang, X. (2024). Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies. Cancer Communications, 44, 1071–1097. https://doi.org/10.1002/cac2.12587
Teo, A., Yau, C., Low, C., Pereira, J., Ng, J., Soong, T., Lo, J., & Yang, V. (2024). Effectiveness of immune checkpoint inhibitors and other treatment modalities in patients with advanced mucosal melanomas: A systematic review and individual patient data meta-analysis. eClinicalMedicine, 77. https://doi.org/10.1016/j.eclinm.2024.102870
Touchaei, A., & Vahidi, S. (2024). MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: Targeting PD-1/PD-L1 and CTLA-4 pathways. Cancer Cell International, 24. https://doi.org/10.1186/s12935-024-03293-6
Ugurel, S., Röhmel, J., Ascierto, P., Becker, J., Flaherty, K., Grob, J., Hauschild, A., Larkin, J., Livingstone, E., Long, G., Lorigan, P., McArthur, G., Ribas, A., Robert, C., Zimmer, L., Schadendorf, D., & Garbe, C. (2020). Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - update 2019. European Journal of Cancer, 130, 126–138. https://doi.org/10.1016/j.ejca.2020.02.021
Vukadin, S., Khaznadar, F., Kizivat, T., Včev, A., & Smolić, M. (2021). Molecular mechanisms of resistance to immune checkpoint inhibitors in melanoma treatment: An update. Biomedicines, 9. https://doi.org/10.3390/biomedicines9070835
Wang, X., Borsky, K., Proctor, D., Goodall, R., Marshall, D., Dobell, W., Salciccioli, J., Matin, R., Shalhoub, J., & El-Muttardi, N. (2025). Trends in cutaneous melanoma mortality and incidence in European Union 15+ countries between 1990 and 2019. Journal of the European Academy of Dermatology and Venereology, 39, 1285–1296. https://doi.org/10.1111/jdv.20524
Weber, J., Carlino, M., Khattak, A., Meniawy, T., Ansstas, G., Taylor, M., Kim, K., Mckean, M., Long, G., Sullivan, R., Faries, M., Tran, T., Cowey, C., Pecora, A., Shaheen, M., Segar, J., Medina, T., Atkinson, V., Gibney, G., …, Zaks, T. (2024). Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study. Lancet. https://doi.org/10.1016/s0140-6736(23)02268-7
Willsmore, Z., Coumbe, B., Crescioli, S., Reci, S., Gupta, A., Harris, R., Chenoweth, A., Chauhan, J., Bax, H., McCraw, A., Cheung, A., Osborn, G., Hoffmann, R., Nakamura, M., Laddach, R., Geh, J., Ross, A., Healy, C., Tsoka, S., …, Karagiannis, S. (2021). Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. European Journal of Immunology, 51. https://doi.org/10.1002/eji.202048747
Zhang, T., Xu, H., Zheng, X., Xiong, X., Zhang, S., Yi, X., Li, J., Wei, Q., & Ai, J. (2023). Clinical benefit and safety associated with mRNA vaccines for advanced solid tumors: A meta‐analysis. MedComm, 4. https://doi.org/10.1002/mco2.286
Ziogas, D., Theocharopoulos, C., Koutouratsas, T., Haanen, J., & Gogas, H. (2022). Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome? Cancer Treatment Reviews, 113, 102499. https://doi.org/10.1016/j.ctrv.2022.102499
Ziogas, D., Theocharopoulos, C., Lialios, P., Foteinou, D., Koumprentziotis, I., Xynos, G., & Gogas, H. (2023). Beyond CTLA-4 and PD-1 inhibition: Novel immune checkpoint molecules for melanoma treatment. Cancers, 15. https://doi.org/10.3390/cancers15102718
Zoroddu, S., & Bagella, L. (2025). Next-generation mRNA vaccines in melanoma: Advances in delivery and combination strategies. Cells, 14. https://doi.org/10.3390/cells14181476
Şahin, U., Oehm, P., Derhovanessian, E., Jabulowsky, R., Vormehr, M., Gold, M., Maurus, D., Schwarck-Kokarakis, D., Kuhn, A., Omokoko, T., Kranz, L., Diken, M., Kreiter, S., Haas, H., Attig, S., Rae, R., Ćuk, K., Kemmer-Brück, A., Breitkreuz, A., …, Türeci, Ö. (2020). An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature, 1–6. https://doi.org/10.1038/s41586-020-2537-9
Коротаева, А., Апанович, Н., Брага, Э., Матвеев, В., & Карпухин, А. (2020). Современные достижения в иммунотерапии рака почки. Onkourologiâ, 15, 30–38. https://doi.org/10.17650/1726-9776-2019-15-4-30-38
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Artur Marcysiak, Patrycja Mularczyk, Nina Polek, Małgorzata Sikorska, Wojciech Łysoniewski, Tomasz Mruzek, Magdalena Kiełbasiewicz, Karolina Zawadzka, Aleksandra Marcysiak
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
